Day One Biopharmaceuticals, Inc.
DAWN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $131 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $5 | $0 | $1 | $0 |
| Gross Profit | $126 | -$0 | -$1 | -$0 |
| % Margin | 96% | – | – | – |
| R&D Expenses | $228 | $131 | $86 | $44 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $115 | $75 | $61 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $343 | $206 | $146 | $73 |
| Operating Income | -$217 | -$206 | -$147 | -$73 |
| % Margin | -165.7% | – | – | – |
| Other Income/Exp. Net | $129 | $17 | $5 | -$0 |
| Pre-Tax Income | -$88 | -$189 | -$142 | -$73 |
| Tax Expense | $7 | $0 | $0 | $0 |
| Net Income | -$95 | -$189 | -$142 | -$71 |
| % Margin | -72.8% | – | – | – |
| EPS | -1.02 | -2.37 | -2.02 | -1.14 |
| % Growth | 57% | -17.3% | -77.2% | – |
| EPS Diluted | -1.02 | -2.37 | -2.02 | -1.14 |
| Weighted Avg Shares Out | 94 | 80 | 65 | 62 |
| Weighted Avg Shares Out Dil | 94 | 80 | 65 | 62 |
| Supplemental Information | – | – | – | – |
| Interest Income | $20 | $17 | $5 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $0 | $1 | $0 |
| EBITDA | -$86 | -$189 | -$142 | -$73 |
| % Margin | -65.8% | – | – | – |